This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
-
ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
Alaska Oncology and Hematology, Anchorage, Alaska, United States, 99508
Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona, United States, 85054
Local Institution - 001-807, Scottsdale, Arizona, United States, 85258
Local Institution - 001-873-A, Tucson, Arizona, United States, 85704
USOR - Arizona Oncology - Tucson - Rudasill, Tucson, Arizona, United States, 85704
Local Institution - 001-840-B, Bellflower, California, United States, 90706
Beverly Hills Cancer Center, Beverly Hills, California, United States, 90211
City of Hope - Duarte (Main Campus), Duarte, California, United States, 91010
Local Institution - 001-850-K, Dublin, California, United States, 94568
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Mirati Therapeutics Inc.,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2026-01-16